Screening for lung cancer
58 results
1 - 58
Screening for lung cancer 
Screening for lung cancer: Cochrane systematic review
Screening smokers for lung cancer with low-dose CT decreases lung cancer mortality- Consequences of screening for lung cancer (NELSON)
- USPSTF recommends lung cancer screening for some smokers
- Low‐dose computed tomography (LDCT) screening for lung cancer‐related mortality New
- Uncertain risks and benefits of CT screening for lung cancer
- CT screening for lung cancer: more cancers detected, no mortality benefit (DANTE)
- Lower mortality with CT screening for lung cancer, but at very high cost
- Annual screening chest x-ray does not reduce lung cancer mortality
- Italian lung cancer screening findings consistent with US National Lung Screening Trial results (ITALUNG)
- Low-dose CT screening of smokers decreases lung cancer deaths, but not overall mortality
- Systematic review: lung cancer screening with CT decreases mortality but with significant harms
- Lung cancer screening requires additional imaging in 40% of patients in real world
- Lung cancer screening is cost effective, but only if done correctly
- Spiral CT detects early lung cancer, but screening use is premature
- USPSTF 2021 recommends annual lung cancer screening based on shared decision-making in high-risk adults (B recommendation)
- Population screening for cancer
- Low-dose CT screening decreases mortality in heavy smokers
- High false-positive rate with lung cancer screening
- Lung cancer screening with low-dose CT does not affect smoking cessation rates
- Lung cancer screening may increase the likelihood of smoking cessation
- Volume-based low-dose CT screening reduces lung cancer–specific mortality (NELSON)
- One in five patients overdiagnosed with lung CA screening
- Adherence to lung cancer screening is relatively poor after baseline scan
- After community lung cancer screening, rates of follow-up imaging are lower but the rates of some procedures are higher
- Lung cancer
- Screening for ovarian cancer
- High false positive rate in repeated, multimodal screening for cancers (PLCO)
- CT finds early lung Ca but carries risk (PLuSS)
- Prostate cancer screening: no mortality benefit after 13 years of follow-up (PLCO)
- Probability of cancer in high-risk patients with pulmonary nodules detected by low-dose screening CT
- PSA screening does not reduce mortality from prostate CA (PLCO)
- Prostate cancer screening: no mortality benefit after 15 years of follow-up (PLCO)
- Screening CA-125 and transvaginal ultrasound does not reduce ovarian cancer mortality
- Need to screen 1055 and treat 37 to prevent one prostate CA death over 11 years (ERSPC)
- Ovarian cancer screening does not improve outcomes (UKCTOCS)
- Screening for ovarian cancer with CA-125/ultrasound algorithm does not reduce mortality (UKCTOCS)
- Chemotherapy for non‐small cell lung cancer Stable (no update expected for reasons given in 'What's new')
- PSA for screening of prostate cancer
- PSA screening has marginal effect on mortality in European study (ERSPC)
- Myositis
- Impact of PSA screening on quality of life
- Flex sig reduces incidence and mortality of colorectal cancer
- Screening for prostate cancer New search for studies and content updated (no change to conclusions)
- Systematic screening and assessment of psychosocial well‐being and care needs of people with cancer Edited (no change to conclusions)
- Post-operative radiotherapy for ductal carcinoma in situ of the breast: Cochrane systematic review
- Alcoholic liver disease (ALD)
- Lymphomas
- Clinical, functional, and demographic factors predict 10-year mortality in adults older than 50
- Anti‐epidermal growth factor receptor therapy for glioblastoma in adults Edited (no change to conclusions)
- Chemotherapy for advanced gastric cancer: Cochrane systematic review